Adtalem Global Education Reports Significant Growth in Q2 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy ATGE?
Source: Newsfilter
- Enrollment Growth: Adtalem Global Education reported a total student enrollment of 97,010 in Q2 FY2026, reflecting a 6.3% year-over-year increase and marking the tenth consecutive quarter of growth, demonstrating the company's strong capability to meet the rising demand for healthcare education.
- Revenue and Profit Increase: The company achieved revenue of $503.4 million in Q2, up 12.4% year-over-year, with adjusted earnings per share reaching $2.43, a 34.3% increase from the previous year, reflecting successful strategies in operational efficiency and market demand.
- Share Repurchase Program: Adtalem completed a $150 million share repurchase program and announced a new $750 million repurchase plan through 2028, indicating strong confidence in future growth and commitment to shareholder returns.
- Future Outlook: The company projects FY2026 revenue between $1.9 billion and $1.94 billion, with adjusted earnings per share expected to range from $7.80 to $8.00, highlighting a positive outlook for expanding market share and enhancing profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATGE
Wall Street analysts forecast ATGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATGE is 163.67 USD with a low forecast of 158.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 103.220
Low
158.00
Averages
163.67
High
170.00
Current: 103.220
Low
158.00
Averages
163.67
High
170.00
About ATGE
Adtalem Global Education Inc. is a provider of healthcare education in the United States, preparing a diverse workforce with academic programs. Its healthcare programs include nursing, medicine, veterinary medicine, social and behavioral sciences and more. Its segments include Chamberlain, Walden, and Medical and Veterinary. Chamberlain segment offers degree and certificate programs in the nursing and health professions postsecondary education industry. Walden segment offers degree and certificate programs, including those in nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice. Medical and Veterinary segment offers degree and certificate programs in the medical and veterinary postsecondary education industry. This segment includes American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adtalem Rebrands to Covista Amid Strategic Transformation
- Company Rebranding: Adtalem Global Education is rebranding to Covista, marking the completion of its strategic transformation, with trading under the ticker CVSA on the NYSE set to begin on February 24, 2026, enhancing brand recognition and market positioning.
- Focus on Healthcare Education: The company shifted its focus to healthcare four years ago and now operates five accredited healthcare institutions in the U.S., serving over 97,000 students and 385,000 alumni, addressing the growing demand for healthcare professionals.
- Capacity Expansion Plans: Covista is looking to expand its educational capacity to help address the shortage of healthcare workers, a strategy that not only enhances the company's competitiveness in the healthcare education market but also contributes to providing more qualified healthcare professionals to society.
- Financial Performance: Covista's latest earnings report indicates an adjusted EPS guidance increase to 17-20% growth, with continued enrollment momentum showcasing the company's strong performance in healthcare education, further solidifying its market position.
See More
Adtalem Rebrands as Covista, Focuses on Healthcare Education
- Rebranding Initiative: Adtalem Global Education has announced its rebranding to Covista, marking the completion of a four-year transformation into America's largest healthcare educator, with plans to trade under the ticker CVSA on the NYSE starting February 24, 2026.
- Educational Scale: Covista operates five accredited institutions serving over 97,000 students and 385,000 alumni, graduating 24,000 healthcare professionals annually, including 10% of America's nurses, underscoring its critical role in healthcare workforce development.
- Addressing Workforce Crisis: The Covista Care Capacity Monitor reveals that the U.S. healthcare workforce shortage is directly impacting patient care quality, necessitating immediate collaborative action among educators, employers, and policymakers to tackle this urgent issue.
- Investment Commitment: Covista has launched the “Covista Open Doors” initiative, aimed at inspiring individuals to pursue healthcare careers through career exploration, scholarships, and mental health support, ensuring a sustainable pipeline of future healthcare professionals.
See More
Covista's Strategic Transformation Enhances Healthcare Education
- Rebranding and Strategic Positioning: Adtalem Global Education announced its name change to Covista, marking the completion of a four-year transformation into America's largest healthcare educator, with plans to trade under the ticker CVSA on February 24, 2026, highlighting its critical role in healthcare workforce development.
- Graduate Numbers and Impact: Covista graduates 24,000 healthcare professionals annually, including 10% of America's nurses, and produces twice as many MDs as any other U.S. medical school, underscoring its significance in addressing the healthcare talent shortage.
- New Research Reveals Crisis Status: The Covista Care Capacity Monitor indicates over 702,000 healthcare job vacancies each month, with only 306,000 unemployed healthcare workers available to fill them, emphasizing the severe human resource crisis facing the healthcare industry.
- Investment and Future Commitment: Covista will unveil its long-term strategy to expand healthcare education capacity at the Investor Day on February 24, emphasizing investment priorities aimed at addressing workforce shortages, which is expected to generate attractive returns for shareholders.
See More
Peregrine Exits Entire Position in Adtalem Global Education
- Position Change: Peregrine Asset Advisers, Inc. fully exited its position in Adtalem Global Education in Q4 by selling 69,012 shares for an estimated $10.66 million, indicating a strategic shift in their investment focus.
- Financial Performance: Despite Adtalem's strong fiscal Q2 results, with revenue rising 12.4% year-over-year to $503 million and adjusted EPS increasing 34% to $2.43, Peregrine's exit may reflect a decision based on opportunity costs rather than business weakness.
- Market Reaction: As of January 30, Adtalem's shares were priced at $103.55, down about 1% over the past year, suggesting that while the company maintains solid performance, its competitive position in the education services market may be under pressure.
- Investment Strategy: Peregrine's portfolio is heavily weighted towards large-cap technology and index-based strategies, indicating a cautious stance towards mid-cap education services like Adtalem, which may not meet their growth expectations amid broader market trends.
See More
Adtalem Global Education Q2 Earnings Highlights
- Enrollment Growth: Adtalem reported total enrollment exceeding 97,000 students in Q2, reflecting over 6% growth year-over-year, with Walden achieving 52,400 students, indicating strong performance and competitive advantage in the education market.
- Significant Financial Performance: The company reported Q2 revenue of $503.4 million, a 12.4% increase, with adjusted EBITDA reaching $154.9 million and an EBITDA margin of 30.8%, showcasing ongoing improvements in operational efficiency and profitability.
- Raised EPS Guidance: Adtalem raised its adjusted EPS guidance from $7.60-$7.90 to $7.80-$8.00, targeting a growth rate of 17%-20%, reflecting confidence in future financial performance and sustained profitability.
- Strategic Investments and Market Expansion: The company plans to present a multi-year growth framework at the upcoming Investor Day, including capacity expansion plans and new revenue streams, further solidifying its market position in the education sector.
See More
Adtalem Global Education Reports Significant Growth in Q2 Results
- Enrollment Growth: Adtalem Global Education reported a total student enrollment of 97,010 in Q2 FY2026, reflecting a 6.3% year-over-year increase and marking the tenth consecutive quarter of growth, demonstrating the company's strong capability to meet the rising demand for healthcare education.
- Revenue and Profit Increase: The company achieved revenue of $503.4 million in Q2, up 12.4% year-over-year, with adjusted earnings per share reaching $2.43, a 34.3% increase from the previous year, reflecting successful strategies in operational efficiency and market demand.
- Share Repurchase Program: Adtalem completed a $150 million share repurchase program and announced a new $750 million repurchase plan through 2028, indicating strong confidence in future growth and commitment to shareholder returns.
- Future Outlook: The company projects FY2026 revenue between $1.9 billion and $1.94 billion, with adjusted earnings per share expected to range from $7.80 to $8.00, highlighting a positive outlook for expanding market share and enhancing profitability.
See More
Adtalem Rebrands to Covista Amid Strategic Transformation
- Company Rebranding: Adtalem Global Education is rebranding to Covista, marking the completion of its strategic transformation, with trading under the ticker CVSA on the NYSE set to begin on February 24, 2026, enhancing brand recognition and market positioning.
- Focus on Healthcare Education: The company shifted its focus to healthcare four years ago and now operates five accredited healthcare institutions in the U.S., serving over 97,000 students and 385,000 alumni, addressing the growing demand for healthcare professionals.
- Capacity Expansion Plans: Covista is looking to expand its educational capacity to help address the shortage of healthcare workers, a strategy that not only enhances the company's competitiveness in the healthcare education market but also contributes to providing more qualified healthcare professionals to society.
- Financial Performance: Covista's latest earnings report indicates an adjusted EPS guidance increase to 17-20% growth, with continued enrollment momentum showcasing the company's strong performance in healthcare education, further solidifying its market position.
See More
Adtalem Rebrands as Covista, Focuses on Healthcare Education
- Rebranding Initiative: Adtalem Global Education has announced its rebranding to Covista, marking the completion of a four-year transformation into America's largest healthcare educator, with plans to trade under the ticker CVSA on the NYSE starting February 24, 2026.
- Educational Scale: Covista operates five accredited institutions serving over 97,000 students and 385,000 alumni, graduating 24,000 healthcare professionals annually, including 10% of America's nurses, underscoring its critical role in healthcare workforce development.
- Addressing Workforce Crisis: The Covista Care Capacity Monitor reveals that the U.S. healthcare workforce shortage is directly impacting patient care quality, necessitating immediate collaborative action among educators, employers, and policymakers to tackle this urgent issue.
- Investment Commitment: Covista has launched the “Covista Open Doors” initiative, aimed at inspiring individuals to pursue healthcare careers through career exploration, scholarships, and mental health support, ensuring a sustainable pipeline of future healthcare professionals.
See More
Covista's Strategic Transformation Enhances Healthcare Education
- Rebranding and Strategic Positioning: Adtalem Global Education announced its name change to Covista, marking the completion of a four-year transformation into America's largest healthcare educator, with plans to trade under the ticker CVSA on February 24, 2026, highlighting its critical role in healthcare workforce development.
- Graduate Numbers and Impact: Covista graduates 24,000 healthcare professionals annually, including 10% of America's nurses, and produces twice as many MDs as any other U.S. medical school, underscoring its significance in addressing the healthcare talent shortage.
- New Research Reveals Crisis Status: The Covista Care Capacity Monitor indicates over 702,000 healthcare job vacancies each month, with only 306,000 unemployed healthcare workers available to fill them, emphasizing the severe human resource crisis facing the healthcare industry.
- Investment and Future Commitment: Covista will unveil its long-term strategy to expand healthcare education capacity at the Investor Day on February 24, emphasizing investment priorities aimed at addressing workforce shortages, which is expected to generate attractive returns for shareholders.
See More
Peregrine Exits Entire Position in Adtalem Global Education
- Position Change: Peregrine Asset Advisers, Inc. fully exited its position in Adtalem Global Education in Q4 by selling 69,012 shares for an estimated $10.66 million, indicating a strategic shift in their investment focus.
- Financial Performance: Despite Adtalem's strong fiscal Q2 results, with revenue rising 12.4% year-over-year to $503 million and adjusted EPS increasing 34% to $2.43, Peregrine's exit may reflect a decision based on opportunity costs rather than business weakness.
- Market Reaction: As of January 30, Adtalem's shares were priced at $103.55, down about 1% over the past year, suggesting that while the company maintains solid performance, its competitive position in the education services market may be under pressure.
- Investment Strategy: Peregrine's portfolio is heavily weighted towards large-cap technology and index-based strategies, indicating a cautious stance towards mid-cap education services like Adtalem, which may not meet their growth expectations amid broader market trends.
See More
Adtalem Global Education Q2 Earnings Highlights
- Enrollment Growth: Adtalem reported total enrollment exceeding 97,000 students in Q2, reflecting over 6% growth year-over-year, with Walden achieving 52,400 students, indicating strong performance and competitive advantage in the education market.
- Significant Financial Performance: The company reported Q2 revenue of $503.4 million, a 12.4% increase, with adjusted EBITDA reaching $154.9 million and an EBITDA margin of 30.8%, showcasing ongoing improvements in operational efficiency and profitability.
- Raised EPS Guidance: Adtalem raised its adjusted EPS guidance from $7.60-$7.90 to $7.80-$8.00, targeting a growth rate of 17%-20%, reflecting confidence in future financial performance and sustained profitability.
- Strategic Investments and Market Expansion: The company plans to present a multi-year growth framework at the upcoming Investor Day, including capacity expansion plans and new revenue streams, further solidifying its market position in the education sector.
See More
Adtalem Global Education Reports Significant Growth in Q2 Results
- Enrollment Growth: Adtalem Global Education reported a total student enrollment of 97,010 in Q2 FY2026, reflecting a 6.3% year-over-year increase and marking the tenth consecutive quarter of growth, demonstrating the company's strong capability to meet the rising demand for healthcare education.
- Revenue and Profit Increase: The company achieved revenue of $503.4 million in Q2, up 12.4% year-over-year, with adjusted earnings per share reaching $2.43, a 34.3% increase from the previous year, reflecting successful strategies in operational efficiency and market demand.
- Share Repurchase Program: Adtalem completed a $150 million share repurchase program and announced a new $750 million repurchase plan through 2028, indicating strong confidence in future growth and commitment to shareholder returns.
- Future Outlook: The company projects FY2026 revenue between $1.9 billion and $1.94 billion, with adjusted earnings per share expected to range from $7.80 to $8.00, highlighting a positive outlook for expanding market share and enhancing profitability.
See More
